Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter infusion may be just as good for preventing repeat variceal bleeding

NCT ID NCT03624517

Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving the drug octreotide for 24 hours instead of the usual 72 hours could prevent early rebleeding from esophageal varices in people with cirrhosis. The trial included 34 adults with active bleeding from varices who underwent endoscopic banding. The goal was to see if the shorter infusion was safe and effective, but the study was stopped early, so the findings are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
octreotide
What this could lead to
If successful, this could show that a shorter 24-hour octreotide infusion is just as safe and effective as the standard 72-hour regimen, potentially reducing hospital stay and treatment burden.
What could go wrong
The trial was terminated early with only 34 participants, so results are limited and may not be reliable. It is unclear if the shorter infusion truly prevents rebleeding as well as the longer one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

34 people

The number who actually took part.

Started

Sep 2018

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult males and females who are 18 years of age or older. 2. Evidence or suspicion of upper gastrointestinal bleed (GIB) 3. Patient with known or suspected cirrhosis 4. Upper GIB secondary to bleeding esophageal varices as show by esophageal endoscopy, requiring endoscopic band ligation (EBL) at presentation 5. Willing and able to provide informed consent for study, or have a Legally authorized representative (LAR) provide consent if the patient is unable to do so Exclusion Criteria: 1. Known upper gastrointestinal malignancy 2. Bleeding from gastric varices, with or without esophageal varices 3. Use of any other endoscopic method to stop GI bleeding beyond endoscopic band ligation 4. Variceal bleeding in the last 90 days 5. History of transjugular, intrahepatic, portosystemic shunt (TIPS) or vascular decompression surgery 6. Pregnant females 7. Incarcerated individuals 8. Myocardial infarct, cerebrovascular accident, sepsis, respiratory failure, or severe intercurrent illness within the previous 6 weeks 9. Non-cirrhotic portal hypertension causing esophageal varices 10. Known or suspected allergy to octreotide

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bleeding esophageal varices are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver esophageal varices Gastrointestinal Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bleeding esophageal varices Esophageal varices Liver cirrhoses Upper gastrointestinal bleeding

Contacts and locations

Locations

  • Brooke Army Medical Center

    Houston, Texas, 78234, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Texas Tech University Health Sciences Center

    El Paso, Texas, 79905, United States

  • The Ohio state University

    Columbus, Ohio, 43210, United States

  • The University of Texas at Austin

    Austin, Texas, 78712, United States

  • University of Florida Health

    Jacksonville, Florida, 32209, United States

  • University of Illinois at Chicago

    Chicago, Illinois, 60607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.